Welcome to the Novartis Sponsored Dinner Symposium
Optimising Adjuvant Management in HR+ HER2- Early Breast Cancer: Evolving Perspectives on Patient Selection.
You’re invited to an engaging and practical symposium exploring the evolving management of hormone receptor-positive, HER2-negative early breast cancer (HR+/HER2– eBC). As clinical evidence continues to mature, clinicians are increasingly faced with decisions around identifying which patients may benefit most from adjuvant treatment and how best to apply emerging data in everyday practice.
Join Dr Belinda Yeo, together with expert panellists Dr Richard De Boer, Dr Louisa Lo and Dr Stephen Luen, as they explore:
- The latest evidence shaping adjuvant treatment in HR+/HER2– early breast cancer.
- Understanding risk profiles and patient selection in contemporary clinical practice.
- Practical considerations for integrating evolving evidence into local treatment pathways.
- An interactive, case-based panel discussion exploring real-world management challenges and providing the opportunity to ask questions of our expert faculty.
Don’t miss this opportunity to gain practical insights from leading breast cancer specialists, explore contemporary approaches to patient selection and adjuvant treatment, and connect with colleagues from across the oncology community. We look forward to seeing you there!
Meet our Guest Speakers
We are pleased to introduce the following speakers at the Novartis-sponsored Breakfast Symposium.
Belinda Yeo
Conference Guest Speaker
Belinda Yeo
Conference Guest Speaker
Dr Belinda Yeo is jointly appointed to the Austin Hospital in Melbourne, Australia, as a Medical Oncologist and to the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer.
She trained in Sydney before joining the Breast Unit at The Royal Marsden Hospital, London as a Clinical and Research Fellow. She completed a Master’s Degree at The University of London and The Institute of Cancer Research in novel genomic and non-molecular breast cancer risk assays.
She is co-lead of the VCCC Research and Education of the Breast Tumour Stream, she is a clinical trial investigator and continues her translational research investigating improving personalisation and minimising toxicities for patients with breast cancer.
Louisa Lo
Symposium Guest Speaker
Louisa Lo
Symposium Guest Speaker
Dr Louisa Lo is a Specialist Physician in Medical Oncology at the Perth Breast Cancer Institute, Breast Cancer Research Centre (BCRC)-WA at Hollywood Private Hospital.
Her immediate focus is on familial breast cancer, cancer prevention, breast cancer management, and new drug studies. Louisa works at the Perth Breast Cancer Institute, Breast Cancer Research Centre (BCRC) WA at Hollywood Private Hospital. She also consults at the breast cancer medical oncology clinics at Sir Charles Gairdner Hospital.
As the Education lead of BCRC-WA, she provides updated clinical education through authoring medical pamphlets, newsletters, and presentations to patients, clinicians, and medical trainees.
Dr Lo graduated from the University of Manchester (UK) with Honours in 2009. She completed her breast cancer oncology fellowship training at the Peter MacCallum Breast Cancer Unit in Melbourne and continued working there as a medical oncologist after her training was complete.
Dr Lo was awarded the prestigious National Health and Medical Research Council PhD scholarship and RACP excellence award in 2017. She is currently completing her PhD in breast cancer liquid biopsy and is interested in using this as a tool to personalise breast cancer treatment for patients.
Dr Lo has been a principal investigator for breast cancer clinical trials and has established her own investigator-initiated studies with sites recruiting in Melbourne and Adelaide.
She has a book chapter and high-impact international cancer journal publications such as the British Journal of Cancer, PLOS Medicine, and Cancer Discovery, and is a reviewer for international cancer journals. She is also a clinical examiner for the FRACP medical physician specialist examinations.
Richard De Boer
Symposium Guest Speaker
Richard De Boer
Symposium Guest Speaker
Dr Richard De Boer is a Melbourne-based medical oncologist who treats people with breast and lung cancer. He is a compassionate communicator and will devise treatment plans to realise the best possible outcome.
Dr Richard De Boer is an accomplished medical oncologist with primary interests in breast and lung cancer. His breast cancer interest focus is on endocrine therapy and mechanisms of resistance, and treatment-induced bone loss and bone metastases. His lung cancer interests are targeted therapies, predictors of response/survival, and small cell lung cancer.
Richard completed his general medical training and then medical oncology training at the Royal Melbourne Hospital. In 1997 he undertook a three year breast and lung cancer clinical research Fellowship at the Royal Marsden Hospital in London. He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice.
Richard is actively involved in clinical research, and is the principal investigator in both local and international studies.
Stephen Luen
Symposium Guest Speaker
Stephen Luen
Symposium Guest Speaker
Stephen Luen is a Medical Oncologist and translational researcher at the Peter MacCallum Cancer Centre with specialist interests in breast cancer, sarcoma, and phase 1 trials.
He completed his PhD under the primary supervision of Professor Sherene Loi in 2021, investigating genomic landscapes and drivers in hormone receptor-positive, HER2-negative early breast cancers, and continues to work closely with the lab as a postdoctoral scientist.
His current research interests include the study of genomic and immune biomarkers in breast cancer, with a particular focus on investigating biological characteristics and developing clinical trials for high-risk subgroups of patients.
Additionally, he has research interests in Precision Oncology approaches and the clinical development of novel therapeutic agents through early-phase clinical trials.